Wang J, et al. - In multidrug-resistant tuberculosis (MDR-TB) patients, researchers examined if additional benefits could be achieved with the use of cycloserine (CS) as well as the incidence and related risk factors of adverse drug reactions (ADRs) from CS. They retrospectively reviewed 623 MDR-TB cases who received regimens containing CS. Findings suggest, in the Chinese population, the could be achievement of a very positive outcome with a CS-containing regimen in the treatment of MDR-TB, with good tolerance. Adverse outcomes of MDR-TB patients were more frequently observed among those who were elderly, had prolonged previous exposure to and history of anti-TB drugs, and pre-existing co-morbidity. The most frequently observed ADR was hyperuricemia (22.8%) among these cases, while the administration of CS was most notably associated with ADRs comprising psychiatric symptoms, accounting for 4.3% (27/623) of the study population.